Physician profile
Alexander Davis
NPI 1285160879
$6,093.78
in general payments reported to CMS, 2019-2025
25 companies · $1,460 in 2025
The $1,460 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $177 · 2021: $346 · 2022: $916 · 2023: $941 · 2024: $1,473 · 2025: $1,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,788 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,787.53 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.61 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $510.49 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $470.57 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $404.77 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $404.11 | 2019-2025 | |
| Lilly USA, LLC | $273.20 | 2020-2024 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $270.48 | 2024-2025 | |
| Ucb, INC. | $260.95 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $260.85 | 2019-2025 | Nemluvio |
| Organogenesis INC. | $233.15 | 2021-2025 | Apligraf |
| Novartis Pharmaceuticals Corporation | $225.47 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.58 | 2024-2025 | Spevigo |
| Leo Pharma INC. | $149.83 | 2021-2025 | Adbry, Spevigo |
| Regeneron Healthcare Solutions, INC. | $121.00 | 2023 | Dupixent |
| Incyte Corporation | $116.85 | 2023-2025 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $88.49 | 2023-2025 | Zoryve |
| Amgen INC. | $85.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Genentech USA, INC. | $74.15 | 2022-2023 | Erivedge |
| Allergan, INC. | $43.46 | 2022 | |
| Convatec INC. | $36.05 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $23.28 | 2022 | |
| Kyowa Kirin, INC. | $20.25 | 2021 | |
| Biofrontera INC. | $17.27 | 2021 | |
| Nabriva Therapeutics, Plc | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.